📊 LIPO Key Takeaways
Is Lipella Pharmaceuticals Inc.. (LIPO) a Good Investment?
Lipella Pharmaceuticals faces imminent liquidity crisis with only ~5-6 months of cash runway at current burn rates ($3.8-4.0M annually) against minimal cash reserves of $1.9M. Despite 19.3% YoY revenue growth, the company remains pre-commercial with $216K in revenue against $4.0M in operating losses, demonstrating no viable path to profitability without significant capital infusion.
Lipella shows minimal revenue and extremely negative profitability (operating and net margins below -1,700%), with ROE/ROA deeply negative. Although debt-free with solid near-term liquidity, its ~$3.8M operating cash burn far exceeds the ~$1.9M cash balance, implying a short runway and likely dilutive financing. Until losses narrow materially or non-dilutive funding materializes, fundamentals remain unfavorable.
Why Buy Lipella Pharmaceuticals Inc.. Stock? LIPO Key Strengths
- Positive revenue growth trajectory (+19.3% YoY)
- Solid current ratio of 3.24x provides near-term liquidity cushion
- Minimal debt burden with 0.00x debt-to-equity ratio
- Debt-free balance sheet with strong liquidity (current/quick ratio 3.24x)
- Cash comprises most assets and capex needs are minimal
- Positive YoY revenue growth (+19.3%) from a low base
LIPO Stock Risks: Lipella Pharmaceuticals Inc.. Investment Risks
- Critical cash runway of only 5-6 months at current operating burn rate
- Massive operating losses ($4.0M) relative to negligible revenue ($216K)
- Pre-commercial stage with no approved revenue-generating products evident
- Deeply negative profitability metrics (Operating Margin -1831.7%, Net Margin -1799.1%)
- Going concern risk without near-term financing or major business inflection
- Severe and persistent operating losses with extreme negative margins
- Cash burn outpacing cash on hand, implying near-term dilution risk
- Early-stage pharma execution/regulatory risk with limited revenue visibility
Key Metrics to Watch
- Cash burn rate and remaining runway
- Revenue monetization and clinical trial progress
- Equity financing announcements or partnerships
- Quarterly operating cash flow and cash runway
- Share count and additional paid-in capital (dilution)
Lipella Pharmaceuticals Inc.. (LIPO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.24x current ratio provides a solid financial cushion.
LIPO Profit Margin, ROE & Profitability Analysis
LIPO vs Healthcare Sector: How Lipella Pharmaceuticals Inc.. Compares
How Lipella Pharmaceuticals Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lipella Pharmaceuticals Inc.. Stock Overvalued? LIPO Valuation Analysis 2026
Based on fundamental analysis, Lipella Pharmaceuticals Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lipella Pharmaceuticals Inc.. Balance Sheet: LIPO Debt, Cash & Liquidity
LIPO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lipella Pharmaceuticals Inc..'s revenue has grown significantly by 107% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.16 indicates the company is currently unprofitable.
LIPO Revenue Growth, EPS Growth & YoY Performance
LIPO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $80.4K | -$938.1K | $-0.28 |
| Q2 2025 | $86.7K | -$938.1K | $-0.31 |
| Q1 2025 | $129.4K | -$1.2M | $-0.64 |
| Q3 2024 | $80.4K | -$938.1K | $-1.29 |
| Q2 2024 | $106.7K | -$938.1K | $-0.12 |
| Q1 2024 | $118.0K | -$1.1M | $-0.16 |
| Q3 2023 | $33.1K | -$713.8K | $-0.17 |
| Q2 2023 | $33.1K | -$738.0K | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lipella Pharmaceuticals Inc.. Dividends, Buybacks & Capital Allocation
LIPO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lipella Pharmaceuticals Inc.. (CIK: 0001347242)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIPO
What is the AI rating for LIPO?
Lipella Pharmaceuticals Inc.. (LIPO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIPO's key strengths?
Claude: Positive revenue growth trajectory (+19.3% YoY). Solid current ratio of 3.24x provides near-term liquidity cushion. ChatGPT: Debt-free balance sheet with strong liquidity (current/quick ratio 3.24x). Cash comprises most assets and capex needs are minimal.
What are the risks of investing in LIPO?
Claude: Critical cash runway of only 5-6 months at current operating burn rate. Massive operating losses ($4.0M) relative to negligible revenue ($216K). ChatGPT: Severe and persistent operating losses with extreme negative margins. Cash burn outpacing cash on hand, implying near-term dilution risk.
What is LIPO's revenue and growth?
Lipella Pharmaceuticals Inc.. reported revenue of $216.1K.
Does LIPO pay dividends?
Lipella Pharmaceuticals Inc.. does not currently pay dividends.
Where can I find LIPO SEC filings?
Official SEC filings for Lipella Pharmaceuticals Inc.. (CIK: 0001347242) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIPO's EPS?
Lipella Pharmaceuticals Inc.. has a diluted EPS of $-1.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LIPO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lipella Pharmaceuticals Inc.. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LIPO stock overvalued or undervalued?
Valuation metrics for LIPO: ROE of -261.4% (sector avg: 15%), net margin of -1,799.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LIPO stock in 2026?
Our dual AI analysis gives Lipella Pharmaceuticals Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIPO's free cash flow?
Lipella Pharmaceuticals Inc..'s operating cash flow is $-3.8M, with capital expenditures of $14.4K. FCF margin is -1,758.2%.
How does LIPO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,799.1% (avg: 12%), ROE -261.4% (avg: 15%), current ratio 3.24 (avg: 2).